Uppsala 18thSeptember 2019
Nanexas extends its collaboration with global animal health company
The global animal health company that started the evaluation of PharmaShell® at the beginning of the year has now decided to prolong and extend the evaluation. This continuation is governed by the same agreement signed with the company in December 2018. The evaluation aims to study PharmaShell®-based depot preparations with three different active drug substances in the laboratory environment and in animal studies. The results will form the basis for possible continued product development and out-licensing of PharmaShell® technology.
The company pays for the studies in full. Nanexa receives a small compensation for the work that is being done.
The company’s CEO David Westberg comments:
The initial evaluation of PharmaShell® with the company’s active substances has been successful. I am glad that they now want to go further in their evaluation of our drug delivery platform PharmaShell®. Partly with the two substances we have already worked with, but also with the addition of a completely new substance. With this extended evaluation, we are approaching the opportunity to enter into a more extensive collaboration.
For further information:
Nanexa AB (publ)
David Westberg, VD
Phone: +46 709 42 83 03
E mail: firstname.lastname@example.org
About Nanexa AB (publ)
Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, which is a new and groundbreaking drug delivery system that is expected to have great potential in a number of medical indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with among others, AstraZeneca.